Get the Stockscreener App
21.98
1.71%
0.37
After Hours:
22.05
0.07
+0.32%
Roivant Sciences Ltd stock is traded at $21.98, with a volume of 7.52M.
It is up +1.71% in the last 24 hours and up +4.82% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$21.61
Open:
$21.81
24h Volume:
7.52M
Relative Volume:
0.96
Market Cap:
$15.29B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
3.8903
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+1.29%
1M Performance:
+4.82%
6M Performance:
+104.66%
1Y Performance:
+90.80%
1-Day Range:
$21.15
$22.14
1-Week Range:
$20.78
$22.20
52-Week Range:
$8.73
$23.47
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
21.98 | 15.03B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
A Look At Roivant Sciences (ROIV) Valuation After Brepocitinib Timeline Acceleration And Profitability Outlook Shift - simplywall.st
Why Roivant Sciences Ltd. stock could be next big winner2026 world cup usa national team third place match top scorers high defensive line odds analysis insights - ulpravda.ru
Leerink Partners reiterates Outperform rating on Roivant Sciences stock By Investing.com - Investing.com Australia
Leerink raises price target as Roivant (ROIV) accelerates drug development pipeline - MSN
Penn Davis Mcfarland Inc. Buys 170,456 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Pacer Advisors Inc. Makes New Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Psithera spun out of Roivant with $47.5M and immune, inflammatory focus - BioWorld MedTech
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline - Insider Monkey
Roivant Sciences Insider Sold Shares Worth $28,902,500, According to a Recent SEC Filing - MarketScreener
Book value per share of Roivant Sciences Ltd. – DUS:87S - TradingView — Track All Markets
Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Mayukh Sukhatme Sells 311,873 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Drops By 16.2% - MarketBeat
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock - MarketBeat
Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences Executives Engage in Significant Share Sales - TradingView — Track All Markets
Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Insider Confidence In December 2025's Leading Growth Companies - Yahoo! Finance Canada
Reassessing Roivant Sciences (ROIV) Valuation After Pipeline Progress, NDA Timelines and Genevant Litigation Updates - simplywall.st
Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Is Roivant Sciences Ltd stock positioned for digital transformationGap Down & High Conviction Trade Alerts - moha.gov.vn
What margin trends mean for Roivant Sciences Ltd. stockFibonacci Extensions & Fast Profit Trading Tips - bollywoodhelpline.com
Ramaswamy-Backed Ambros Launches with $125M - Orange County Business Journal
Roivant Sciences president Sukhatme sells $619k in shares By Investing.com - Investing.com Australia
Roivant Sciences president Sukhatme sells $619k in shares - Investing.com UK
How Investors May Respond To Roivant Sciences (ROIV) Accelerating Brepocitinib Timelines And Patent Litigation - simplywall.st
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock - MSN
Why Roivant Sciences Ltd. stock is in analyst buy zone2025 Fundamental Recap & Reliable Entry Point Trade Alerts - Улправда
US Market Recap: What margin trends mean for Roivant Sciences Ltd stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
Sell Signal: Will Roivant Sciences Ltd stock maintain momentum in 2025Weekly Stock Report & Pattern Based Trade Signal System - moha.gov.vn
Can Roivant Sciences Ltd. stock maintain operating marginsJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
How Roivant Sciences Ltd. (87S) stock reacts to fiscal policiesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - Улправда
Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 26,831 Shares - MarketBeat
Pres Sukhatme Sells 26,831 ($619.5K) Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Can Roivant Sciences Ltd. stock double in next 5 yearsWeekly Market Summary & Daily Technical Stock Forecast Reports - ulpravda.ru
Can Roivant Sciences Ltd. stock outperform in 2025 bull marketMarket Activity Summary & High Conviction Buy Zone Alerts - DonanımHaber
Why Roivant Sciences Ltd. stock remains undervaluedVolume Spike & Consistent Return Strategy Ideas - Bölüm Sonu Canavarı
Will Roivant Sciences Ltd. stock maintain momentum in 2025Weekly Stock Analysis & Long-Term Growth Plans - DonanımHaber
Roivant Sciences Insider Sold Shares Worth $39,065,213, According to a Recent SEC Filing - marketscreener.com
Published on: 2025-12-19 09:31:09 - ulpravda.ru
Will Roivant Sciences Ltd. stock deliver shareholder valueQuarterly Trade Report & Long-Term Safe Return Strategies - Улправда
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 777,332 Shares - MarketBeat
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 917,282 Shares of Stock - MarketBeat
Roivant Sciences (ROIV) director discloses indirect sales of common shares - Stock Titan
Owner QVT Financial LP Sells 1,694,614 ($39.1M) Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Why Roivant Sciences Ltd. stock remains resilientJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Why analysts remain bullish on Roivant Sciences Ltd. stock2025 Analyst Calls & Accurate Entry and Exit Point Alerts - Улправда
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Published on: 2025-12-18 16:03:55 - Улправда
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):